Benefits
Calorie burning has never been measured in anyone taking DHZ
The figure of up to 166 extra calories per day comes from retailer marketing copy. No published study reports it, and no study of any kind has measured energy expenditure, respiratory quotient or body fat in a human taking dehydrozingerone. The 12-week mouse study that underpins this ingredient did not use indirect calorimetry at all: it weighed the animals. For scale, the only human thermogenesis data on ginger used 2 g of whole ginger powder in 10 overweight men and found the thermic effect of food rose by 42.7 kcal per day, with no change in total resting energy expenditure. DHZ is a trace constituent of ginger, so even that small number cannot be carried across.
AMPK activation, shown in mouse muscle cells and in mice
In cultured C2C12 mouse skeletal muscle cells, DHZ increased AMPK phosphorylation and glucose uptake, and blocking AMPK or p38 MAPK abolished that effect. In C57BL/6 mice fed a high-fat diet, DHZ at 100 mg/kg/day for 12 weeks raised GLUT4 in skeletal muscle. AMPK activation is a step inside a cell, not a result you can feel or weigh, and it has not been shown to happen in a person taking DHZ. Mitochondrial biogenesis was not measured in that work.
Glucose and insulin improved in high-fat-fed mice, untested in people
In the one animal study behind this claim, mice on a 60% high-fat diet given DHZ at 100 mg/kg/day for 12 weeks had lower blood glucose and insulin and faster glucose clearance than untreated high-fat-fed mice. No blood glucose, insulin or HOMA-IR value has ever been recorded in a human taking dehydrozingerone at any dose. Nobody with prediabetes or metabolic syndrome has been studied on this ingredient, and it is not a treatment for either condition.
Anti-inflammatory activity seen only in cells and rodents
DHZ and its semisynthetic derivatives reduce NF-kB and COX-2 signalling in stimulated mouse macrophage cultures and in rodent inflammation models, and a 2016 medicinal chemistry review catalogues anti-inflammatory activity among its laboratory properties. No inflammatory marker, CRP or IL-6 or any other, has been measured in a human taking DHZ. Calling it a better alternative to curcumin also assumes an absorption advantage that has not been measured in any species.
Free radical scavenging in test tubes and in irradiated mice
DHZ scavenges DPPH, ABTS, superoxide and nitric oxide radicals in cell-free chemical assays. In Swiss albino mice, a 100 mg/kg intraperitoneal injection raised glutathione, glutathione S-transferase and superoxide dismutase. Those are chemistry and rodent results, and the mice were injected rather than fed, which is not how anyone takes a supplement. No oxidative stress marker has been measured in a person taking DHZ, and radical scavenging in a tube routinely fails to predict any antioxidant effect in a living body.
Better absorption than curcumin is assumed, not measured
DHZ is half of the curcumin molecule, smaller and more lipophilic, which is the chemical reason people expect it to absorb better. That expectation has not been tested. A PubMed search for dehydrozingerone and bioavailability returns two records, a review and an in vitro and mouse cancer paper, and neither dosed both compounds and compared blood levels. There is no human pharmacokinetic study of DHZ at all, so no plasma concentration, no half-life and no absorption figure exists for the ingredient, let alone a comparison with curcumin.
Contains no stimulant
Dehydrozingerone is not a stimulant, so it should not produce the jitteriness or sleep disruption caffeine can cause. That is a statement about what the compound is, not evidence that it burns fat. No human study has assessed its effect on heart rate, blood pressure, sleep or body composition, so the absence of stimulation is a chemical expectation rather than a measured tolerability finding.
Several proposed mechanisms, no measured human outcome
DHZ shows antioxidant, anti-inflammatory and AMPK-related activity across separate cell and rodent experiments, which is why it is marketed as doing several things at once. Each of those findings is preclinical and none has been carried into a human trial, so listing them together multiplies mechanisms rather than benefits. As of August 2026 no clinical study of ZinjaBurn or dehydrozingerone is registered on ClinicalTrials.gov or indexed in PubMed or Europe PMC.
Mechanism of action
AMPK activation
AMPK is the cellular energy sensor that switches off anabolic pathways (lipogenesis, gluconeogenesis) and switches on catabolic pathways (fatty acid oxidation, glucose uptake). DHZ increased AMPK phosphorylation in cultured C2C12 mouse muscle cells and in the skeletal muscle of high-fat-fed C57BL/6 mice. This is the proposed explanation for the glucose and weight results seen in those mice. It has not been demonstrated in human tissue, and a mechanism is not an outcome.
Thermogenesis (proposed, never measured)
No thermogenic effect of DHZ has been measured in any species. The 12-week mouse study did not use indirect calorimetry and did not examine brown adipose tissue or uncoupling proteins, and the 166 calories per day figure has no published source. Uncoupling protein activation and brown fat involvement are speculation offered to explain a result nobody has recorded.
Anti-inflammatory pathway modulation
DHZ and its semisynthetic derivatives inhibit NF-kB and COX-2 signalling in lipopolysaccharide-stimulated mouse macrophage cultures and in rodent inflammation models. Structural similarity to curcumin is a reason to look for shared targets, not proof of shared clinical effects, and the claimed absorption advantage over curcumin has never been measured in any species. No human inflammatory endpoint has been tested.
Glucose uptake in cultured mouse muscle cells
In cultured C2C12 mouse muscle cells, DHZ raised glucose uptake through AMPK and p38 MAPK, and inhibiting either kinase abolished the uptake. GLUT4 expression rose in mouse skeletal muscle. Nothing comparable has been measured in human cells or in people. This ingredient is not a treatment for diabetes or prediabetes, and anyone managing blood sugar with medication should speak to their prescriber before adding it.
Antioxidant free radical scavenging
DHZ scavenges DPPH, ABTS, superoxide and nitric oxide radicals in cell-free assays, which its phenolic hydroxyl group and conjugated double bond would predict. In mice given DHZ by intraperitoneal injection rather than by mouth, glutathione, glutathione S-transferase and superoxide dismutase rose. Chemical scavenging power measured in a tube frequently fails to translate into any antioxidant effect in a living person, and that translation has not been tested for DHZ.
Clinical trials
There is no published clinical study of ZinjaBurn or of isolated dehydrozingerone. Searches run in August 2026 returned nothing: PubMed for 'ZinjaBurn' (0 records) and for 'dehydrozingerone AND clinical trial[pt]' (0 records), Europe PMC for 'ZinjaBurn' (0 records), and the ClinicalTrials.gov API for 'dehydrozingerone' and for 'ZinjaBurn' (0 registered studies). NNB Nutrition's own ingredient page lists no study.
None. No person has ever been enrolled in a study of this ingredient.
The claim of up to 166 extra calories burned per day appears in retailer copy and cannot be traced to any published measurement. The nearest human data use whole ginger powder rather than DHZ: in 10 overweight men, 2 g of ginger raised the thermic effect of food by 42.7 kcal/day and left total resting energy expenditure unchanged.
Kim SJ and colleagues, Journal of Cellular and Molecular Medicine 2015 (PMID 25582026). C57BL/6 mice on a 60% high-fat diet received dehydrozingerone at 100 mg/kg/day for 12 weeks, 10 animals per group, alongside experiments in cultured C2C12 mouse skeletal muscle cells.
C57BL/6 mice and cultured mouse C2C12 muscle cells. No humans.
DHZ increased AMPK phosphorylation and glucose uptake in mouse muscle cells, raised GLUT4 expression in mouse skeletal muscle, and in the mice blunted high-fat-diet weight gain and visceral fat accumulation and the rise in glucose and insulin. Blocking AMPK or p38 MAPK abolished the effect on glucose uptake. Energy expenditure, brown fat and uncoupling proteins were not measured. Whether any of this happens in a person taking DHZ is unknown.
The claim that DHZ is better absorbed than curcumin comes from medicinal chemistry commentary, not from a study that dosed both compounds and measured blood levels. A PubMed search for 'dehydrozingerone AND bioavailability' in August 2026 returned 2 records, a review and an in vitro and mouse prostate cancer paper, neither of which compares absorption of the two compounds in the same subjects.
None. No absorption measurement in humans or animals compares the two compounds.
Dehydrozingerone is half of the curcumin molecule and a known curcumin degradation product, so it is smaller and more lipophilic, which is the chemical basis for expecting better absorption. That expectation has not been tested in any species. Being structurally related to curcumin is also not evidence that DHZ produces curcumin's effects, and curcumin's own clinical record is itself mixed. No curcumin trial result should be read across to this ingredient.